---

Meniere's Disease — A Comprehensive Review (50 Marks)

---

1. HISTORICAL BACKGROUND

---

2. EPIDEMIOLOGY

---

3. DEFINITION

1. Episodic vertigo (spontaneous, rotational, lasting 20 min to 24 hours)
2. Fluctuating sensorineural hearing loss (typically low frequency, unilateral)
3. Tinnitus (roaring or low-pitched, unilateral)

---

4. ETIOLOGY AND RISK FACTORS

Primary (Idiopathic)

Proposed Etiological Theories

Secondary Causes

• Syphilis (most important secondary cause — Cummings)
• Otosclerosis
• Paget's disease
• Post-traumatic / post-infective labyrinthine hydrops
• Delayed endolymphatic hydrops (after mumps deafness)

---

5. PATHOPHYSIOLOGY — ENDOLYMPHATIC HYDROPS

Normal Endolymph Physiology

Mechanism of Hydrops

↓ Absorption (Endolymphatic sac dysfunction)
            ↓
  Accumulation of Endolymph (Hydrops)
            ↓
  Distension of Membranous Labyrinth
     ┌──────────────────────────┐
     ↓                          ↓
Cochlear Duct (Scala Media)  Saccule → Utricle → Semicircular canals
     ↓                          ↓
Hearing loss/Tinnitus         Vertigo/Aural fullness

Rupture Theory (Schuknecht)

Ionic Flow Hypothesis (More Recent)

---

6. PATHOLOGICAL ANATOMY

MRI Findings — Endolymphatic Hydrops:

Gross Pathology (Temporal Bone Studies — Hallpike & Cairns)

• Cochlear duct (scala media) enormously distended — Reissner's membrane bulged into scala vestibuli
• Saccule distended, herniated into the oval window niche
• Utricle and semicircular canal ducts dilated
• Endolymphatic sac — fibrous, atrophic, hypoplastic duct

Histological Changes

• Atrophy of stria vascularis (late stage)
• Loss of cochlear hair cells (outer > inner)
• Degeneration of spiral ganglion neurons
• Ruptures and re-healed tears in Reissner's membrane

---

7. STAGES OF MÉNIÈRE'S DISEASE (Paparella Classification)

---

8. CLINICAL FEATURES

The Classic Tetrad (Proctor's Tetrad)

1. Episodic Rotational Vertigo — spontaneous, severe, lasts 20 min–24 hours (Barany criteria), with nausea/vomiting, pallor, sweating
2. Fluctuating Sensorineural Hearing Loss — low-frequency initially (250–1000 Hz), worsens with attacks, eventually permanent
3. Tinnitus — roaring, buzzing, low-pitched; increases before attacks
4. Aural Fullness — sensation of pressure or plugging

Prodromal Symptoms (Aural Pressure / Lermoyez Variant)

• Lermoyez Syndrome: Hearing improves during an attack (inverse Ménière's) — rare

Drop Attacks (Tumarkin's Otolithic Crisis)

• Sudden fall without loss of consciousness
• Due to sudden deformation of otolithic membrane (utricle/saccule)
• Occurs in ~6% of patients (Cummings)

Course of Disease

• Attacks cluster; remissions can last months to years
• Most patients (>80%) have unilateral disease initially
• Bilateral involvement in 10–50% depending on duration of follow-up (Scott-Brown)

---

9. DIAGNOSTIC CRITERIA

AAO-HNS (1995) Revised by Barany Society (2015) — Currently Accepted

Definite Ménière's Disease:

1. Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours
2. Audiometrically documented low-to-medium frequency SNHL in the affected ear on at least one occasion before, during, or after the episode of vertigo
3. Fluctuating aural symptoms (hearing, tinnitus, or fullness) in the affected ear
4. Not better accounted for by another vestibular diagnosis

Probable Ménière's Disease:

• Two or more episodes of vertigo or dizziness lasting 20 min–24 hours
• Fluctuating aural symptoms
• Not better accounted for by another diagnosis

Staging by Pure Tone Audiometry (AAO-HNS 1995)

---

10. INVESTIGATIONS

Audiological Tests

Electrophysiological Tests

Vestibular Tests

Imaging

Blood Tests

• FBS, thyroid function (T3, T4, TSH)
• Lipid profile
• FTA-ABS, VDRL (syphilis)
• Auto-antibodies: ANA, anti-Ro, anti-La, ANCA, anti-68kDa HSP70
• CBC, ESR

---

11. DIFFERENTIAL DIAGNOSIS

---

12. MANAGEMENT

1. Aborting acute attacks (symptomatic relief)
2. Preventing future attacks (prophylaxis)
3. Protecting hearing (hearing preservation)
4. Rehabilitation
5. Definitive ablation in refractory cases

---

MANAGEMENT FLOWCHART (AAO-HNS 2020 Clinical Practice Guideline)

---

A. MANAGEMENT OF ACUTE ATTACK

ACUTE MÉNIÈRE'S ATTACK
        ↓
Bed rest, quiet dark room, head still
        ↓
VESTIBULAR SUPPRESSANTS
  ┌─────────────────────────────────────────────────┐
  │ Prochlorperazine 12.5 mg IM / 3–6 mg buccal    │
  │ Promethazine 25 mg IM                           │
  │ Diazepam 5–10 mg IV/IM (GABA-A agonist)        │
  │ Cinnarizine 15–30 mg oral                       │
  │ Meclizine 25–50 mg oral                         │
  └─────────────────────────────────────────────────┘
        ↓
ANTI-EMETICS
  Ondansetron 4–8 mg IV/oral (if vomiting severe)
  Metoclopramide 10 mg IM
        ↓
IV FLUIDS if dehydrated

---

B. PROPHYLACTIC (LONG-TERM) MEDICAL MANAGEMENT

Step 1: Lifestyle and Dietary Modifications (First-Line)

• Low-sodium diet (1500–2000 mg/day) — reduces endolymph osmolarity (Cummings; Dhingra; Scott-Brown)
• Avoid caffeine, alcohol, nicotine — vasoconstrictors; precipitate attacks
• Adequate hydration — 6–8 glasses of water/day
• Stress management — yoga, counseling, cognitive behavioral therapy
• Regular sleep schedule
• Avoid monosodium glutamate (MSG)

Step 2: Pharmacological Prophylaxis

---

C. INTRATYMPANIC (IT) THERAPY

IT Corticosteroids (IT Dexamethasone / IT Methylprednisolone)

• Indications: Failure of medical therapy; hearing preservation desired; serviceable hearing
• Mechanism: Anti-inflammatory; reduces endolymphatic sac dysfunction
• Technique: Injection through tympanic membrane (inferior-posterior quadrant) or through Mick tube/ventilation tube; patient supine, affected ear up; 0.5–0.8 mL of dexamethasone 4 mg/mL or 24–40 mg/mL methylprednisolone
• Outcomes: Vertigo control 40–70%; hearing improvement ~30%
• Advantage: Non-destructive; hearing preserved
• Repeat: Series of 3–5 injections over 2–4 weeks
• (AAO-HNS Guideline — "May Offer IT Steroids"; Scott-Brown; Cummings)

IT Gentamicin (Chemical Labyrinthectomy)

• Indications: Refractory vertigo; non-serviceable or poor hearing; failed IT steroids
• Mechanism: Aminoglycoside preferentially destroys vestibular hair cells (Type I > Type II); preserves some cochlear function
• Technique: 26–40 mg/mL gentamicin sulfate; inject 0.5–0.8 mL; series of 1–4 injections (titration protocol preferred)
• Protocols:
  • Fixed schedule (weekly × 4)
  • Titration method (inject until nystagmus/imbalance develops — preferred to limit cochlear toxicity)
• Outcomes: Vertigo control 85–95% (best pharmacological ablation); SNHL worsens in 10–30%
• Monitoring: Serial audiometry after each injection
• (AAO-HNS Guideline — "Offer IT Gentamicin" for refractory with serviceable/non-serviceable hearing; Cummings p.2177; Stell & Maran)

---

MANAGEMENT ALGORITHM (Step-ladder Approach)

┌─────────────────────────────────────────────────────────────────────┐
│                   MÉNIÈRE'S DISEASE — STEP-LADDER MANAGEMENT        │
├────────┬────────────────────────────────────────────────────────────┤
│ STEP 1 │ Lifestyle: Low-salt diet, no caffeine/alcohol, stress Mx   │
│        │ + Betahistine + Diuretic                                   │
├────────┼────────────────────────────────────────────────────────────┤
│ STEP 2 │ If Step 1 fails (≥3 months trial):                         │
│        │ Intratympanic Dexamethasone / Methylprednisolone           │
├────────┼────────────────────────────────────────────────────────────┤
│ STEP 3 │ If Step 2 fails:                                            │
│        │ Intratympanic Gentamicin (titration protocol)              │
├────────┼────────────────────────────────────────────────────────────┤
│ STEP 4 │ If Step 3 fails — SURGICAL OPTIONS:                         │
│        │ ┌─ Hearing serviceable → Endolymphatic Sac Surgery /VNS    │
│        │ └─ Hearing non-serviceable → Labyrinthectomy               │
└────────┴────────────────────────────────────────────────────────────┘

---

D. SURGICAL MANAGEMENT

Classification of Surgical Procedures

SURGICAL PROCEDURES FOR MÉNIÈRE'S DISEASE
├── CONSERVATIVE (Hearing-Preserving)
│   ├── Endolymphatic Sac Decompression (ELS Surgery)
│   │   ├── Simple decompression
│   │   └── Endolymphatic sac shunt (to mastoid / subarachnoid)
│   └── Cochleosacculotomy (Fick's Operation) — transcanal
│
├── SEMI-DESTRUCTIVE (Hearing-Preserving + Vestibular Ablation)
│   └── Vestibular Neurectomy (VNS) — retrolabyrinthine / retrosigmoid approach
│
└── DESTRUCTIVE (Non-Hearing-Preserving)
    └── Labyrinthectomy
        ├── Transmastoid Labyrinthectomy
        └── Transcanal Labyrinthectomy

1. Endolymphatic Sac Surgery (ELS)

• Most conservative hearing-preserving procedure
• Types:
  • Simple decompression — mastoidectomy + expose endolymphatic sac; remove bone over sac; no incision
  • Endolymphatic-mastoid shunt (House) — incise sac; insert Silastic/T-tube shunt into mastoid
  • Endolymphatic-subarachnoid shunt (Portmann) — shunt into posterior fossa CSF; rarely done now
• Approach: Cortical mastoidectomy; sac located between sigmoid sinus and posterior semicircular canal (Donaldson's line)
• Results: 70–80% vertigo control; hearing preserved or improved in 70%
• Criticism: Thomsen (Copenhagen Sham Surgery Trial) — sham operation (mastoidectomy alone) produced equal results → controversial; but meta-analyses support real benefit
• (Cummings; Scott-Brown; Stell & Maran; Zakir Hussain)

Donaldson's Line (Surgical Landmark)

A line drawn through the lateral semicircular canal bisecting the posterior
semicircular canal — the endolymphatic sac lies inferior to this line,
between the sac and the sigmoid sinus.

2. Vestibular Neurectomy (VNS)

• Principle: Section of vestibular nerve; preserves cochlear function
• Approaches:
  • Retrolabyrinthine (House) — posterior to semicircular canals, anterior to sigmoid sinus
  • Retrosigmoid (suboccipital) — behind sigmoid sinus; excellent exposure
  • Middle fossa — superior approach; used for superior vestibular nerve
  • Combined retrolabyrinthine-retrosigmoid
• Identification: Eighth nerve complex separated; superior and inferior vestibular nerves sectioned; cochlear nerve preserved
• Results: Vertigo control 90–95%; hearing preserved in >90%
• Risk: CSF leak, facial nerve injury, hearing loss, meningitis
• AAO-HNS Note: "No recommendation regarding VNS/ELS" in 2020 guideline (insufficient evidence grade)
• (Cummings; Scott-Brown; Dhingra)

3. Labyrinthectomy

• Most effective for vertigo control (95–98%)
• Absolute sacrifice of hearing — only for non-serviceable hearing (>50 dB loss, speech discrimination <50%)
• Types:
  • Transmastoid labyrinthectomy: Complete mastoidectomy → remove all 3 semicircular canals → open vestibule → remove all membranous labyrinth structures
  • Transcanal labyrinthectomy (Day): Meatal flap raised → stapedectomy → enter vestibule → remove saccule and utricle
• Cochlear implantation can be done subsequently if contralateral ear deafens
• (Cummings; Stell & Maran; Hazarika; Zakir Hussain)

4. Cochleosacculotomy (Fick's Operation)

• Transcanal procedure under LA
• Strut pick used through round window or via stapes footplate to rupture saccule
• Creates permanent fistula between cochlea and perilymph
• Simple, avoids GA — useful in elderly/poor surgical risk
• Results variable; risk of severe SNHL
• (Scott-Brown; Hazarika)

Surgical Results Summary

---

E. POSITIVE PRESSURE THERAPY (Meniett Device)

• Low-pressure pulses (0.6 bar, 6 Hz) delivered via tympanostomy tube
• Proposed to improve endolymph resorption via oval/round window
• AAO-HNS 2020: "Should NOT offer positive pressure therapy" — evidence insufficient
• (Guideline, p.41)

F. HEARING REHABILITATION

• Hearing Aids — for mild-moderate SNHL; conventional BTE or ITE
• CROS/BiCROS aids — for unilateral profound loss
• Cochlear Implantation — for bilateral profound loss or post-labyrinthectomy
• Bone-anchored hearing aids (BAHA/Osia) — single-sided deafness
• (AAO-HNS Guideline; Cummings)

G. VESTIBULAR REHABILITATION

• NOT indicated for acute attacks (vestibular suppressants preferred acutely)
• Indicated for chronic disequilibrium and compensatory rehabilitation after ablative procedures
• Cawthorne-Cooksey exercises; Brand-Daroff exercises; specific VRT programs
• (AAO-HNS Guideline)

H. PSYCHOLOGICAL AND BEHAVIORAL MANAGEMENT

• Cognitive behavioral therapy (CBT)
• Patient education and support groups
• Treatment of comorbid anxiety and depression (SSRIs)
• Relaxation techniques, mindfulness
• (Scott-Brown; Cummings)

---

13. RECENT ADVANCES

A. Imaging

• Intratympanic Gadolinium MRI (IT-Gd MRI): Gold standard for in-vivo visualization of endolymphatic hydrops. Gadolinium injected intratympanically → absorbed into perilymph but excluded from endolymph → on MRI, endolymph appears dark vs. bright perilymph → allows direct measurement of hydrops grade (Nakashima et al., 2009; Baráthy Society guidelines)
• 4T/7T MRI — ultra-high field imaging for better resolution of labyrinthine structures
• HYDROPS grading scale (Bernaerts): cochlear and vestibular hydrops graded 0–2

B. Genetic Research

• COCH gene mutations — associated with delayed-onset MD-like phenotype (DFNA9)
• DTNA (Dystrobrevin alpha) gene — familial MD
• HLA-DRB1*1101 — associated with bilateral MD in autoimmune context
• Polygenic risk studies ongoing (GWAS)

C. Novel Drug Targets

• High-dose betahistine — BEMED trial showed no effect at 48 mg BD, but observational studies with 144–480 mg/day show promise
• AQP2 (Aquaporin-2) inhibitors — endolymph regulation via aquaporin channels in stria vascularis and inner ear; potential pharmacological target
• Vasopressin (V2R) antagonists (tolvaptan, OPC-31260) — animal models show reduction of hydrops; Phase II trials ongoing

D. Minimally Invasive Procedures

• Pressure equalization tubes + IT drug delivery — sustained-release drug delivery systems (microparticles, hydrogels)
• Round window electrode for gentamicin delivery — improved targeting
• Endolymphatic sac transtympanic drug delivery

E. Immunotherapy

• IV methylprednisolone pulse therapy for autoimmune MD
• Rituximab (anti-CD20) for refractory autoimmune cases

F. Endolymphatic Sac Surgery Advances

• Endoscopic endolymphatic sac surgery — minimally invasive mastoid endoscopy
• MRI-guided stereotactic approaches — experimental

G. Neuromodulation

• Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) — experimental; targeting cortical vestibular areas
• Middle ear pressure therapy with improved devices

H. Cochlear Implantation in MD

• Expanding indications — MD ears with adequate cochlear nerve function showing excellent outcomes post-labyrinthectomy
• Simultaneous labyrinthectomy + cochlear implantation gaining acceptance

I. Biomarkers

• Serum anti-HSP-70 antibodies — potential diagnostic marker for autoimmune subtype
• Endolymph ionic composition analysis (experimental)
• Vestibular evoked myogenic potentials (VEMPs) as surrogate markers of hydrops severity

---

14. PROGNOSIS

• Natural history: 60–80% of patients stabilize within 8–10 years
• Hearing loss progressive in most; ultimate threshold 40–70 dB in affected ear
• Bilateral involvement — up to 50% over lifetime
• Vertigo usually burns out as vestibule degenerates (Schuknecht's "burned-out" MD)
• Quality of life significantly impaired — anxiety, depression, work disability in active disease
• (Cummings; Scott-Brown)

---

15. COMPLICATIONS

---

16. SUMMARY TABLE — KEY POINTS FOR EXAM

---

REFERENCES

1. Bailey & Love's Short Practice of Surgery, 28th Ed. — p. 783
2. Cummings Otolaryngology — Head and Neck Surgery, 7th Ed. — Chapters on Meniere's disease, vestibular neurectomy, labyrinthectomy
3. Scott-Brown's Otorhinolaryngology, Head and Neck Surgery, 8th Ed. — Endolymphatic hydrops, surgical management
4. Stell & Maran's Head and Neck Surgery, 4th Ed. — Inner ear disorders
5. PL Dhingra — Diseases of Ear, Nose and Throat & Head and Neck Surgery, 7th Ed. — Chapter on Ménière's disease
6. Hazarika P — Textbook of ENT & Head Neck Surgery — Ménière's disease, vertigo
7. Zakir Hussain — Textbook of ENT — Inner ear disease management
8. AAO-HNS Clinical Practice Guideline: Ménière's Disease, 2020 (Bhattacharyya N et al., Otolaryngol Head Neck Surg) — p. 41
9. Barany Society Classification of Vestibular Disorders, 2015 — Ménière's disease diagnostic criteria
10. Adrion C et al. (BEMED Trial) — BMJ 2016; Efficacy of betahistine: double-blind randomized trial
11. Nakashima T et al. — Endolymphatic hydrops revealed by intravenous gadolinium injection; Ann Otol Rhinol Laryngol, 2009
12. Hallpike CS, Cairns H — Observations on the pathology of Ménière's syndrome; J Laryngol Otol, 1938
13. Schuknecht HF — Pathology of the Ear, 2nd Ed. — Temporal bone histopathology

---

Exam Tip: For a 50-mark answer, cover: Definition → Epidemiology → Etiology → Pathophysiology (hydrops mechanism with diagram) → Clinical features (tetrad + Lermoyez + Tumarkin) → Investigations (audiogram, ECoG, glycerol test, MRI) → Diagnostic criteria (Barany 2015) → Medical management (stepladder) → IT therapy → Surgical options (ELS, VNS, labyrinthectomy with flowchart) → Recent advances → Prognosis. Use the management flowchart and step-ladder algorithm prominently.